Table 4. Results from meta-analysis of IL-18 gene promoter haplotypes.

		−607A/−137C vs. −607C/−137G		−607A/−137G vs. −607C/−137G		−607C/−137C vs. −607C/−137G
	N	OR	Ph	OR	Ph	OR	Ph
Total	26	1.08(0.97, 1.21)	<0.001	1.01(0.95, 1.08)	<0.001	1.04(0.93, 1.17)	<0.001
Cancer Types
GC	6	1.13(0.76, 1.68)	<0.001	1.07(0.79, 1.45)	<0.001	1.00(0.86, 1.17)	0.389
NC	4	1.26(1.13, 1.40)*	0.569	1.05(0.96, 1.16)	0.951	1.14(1.03, 1.27)*	0.775
GUC	4	0.99(0.83, 1.19)	0.008	0.97(0.90, 1.04)	0.631	1.06(0.92, 1.21)	0.051
GIC	6	1.17(0.94, 1.47)	<0.001	0.99(0.85, 1.14)	0.001	1.16(0.84, 1.59)	<0.001
BC	2	0.98(0.76, 1.27)	0.242	1.09(0.93, 1.27)	0.570	0.88(0.74, 1.04)	0.454
Others	4	0.87(0.56, 1.37)	<0.001	1.05(0.91, 1.20)	0.537	0.83(0.60, 1.17)	0.006
Ethnicities
Asian	18	1.12(0.99, 1.26)	<0.001	1.03(0.96, 1.11)	0.006	1.06(0.98, 1.14)	0.044
Caucasian	6	0.98(0.69, 1.38)	<0.001	0.95(0.82, 1.11)	0.018	0.98(0.64, 1.49)	<0.001
African	1	1.11(0.88, 1.38)	NA	1.03(0.84, 1.25)	NA	1.05(0.85, 1.31)	NA
Mixed	1	0.81(0.56, 1.15)	NA	1.00(0.80, 1.24)	NA	0.81(0.56, 1.15)	NA
Source of Controls
PB	16	0.97(0.83, 1.14)	<0.001	0.98(0.90,1.06)	0.003	0.98(0.82, 1.18)	<0.001
HB	10	1.25(1.10, 1.42)*	0.003	1.06(0.96, 1.18)	0.006	1.15(1.07, 1.23)*	0.487
Sample Size
Large a	4	1.06(0.84, 1.34)	<0.001	1.01(0.94, 1.08)	0.627	1.05(0.92, 1.21)	0.056
Small b	22	1.09(0.96, 1.24)	<0.001	1.02(0.94, 1.10)	<0.001	1.04(0.90, 1.19)	<0.001

GC: Gynecological cancer; NC: Nasopharyngeal carcinoma; GUC: Genitourinary system cancer; GIC: Gastrointestinal cancer; BC: Breast cancer; N: number of studies included; OR: odds ratio; P_h: p value for heterogeneity;

^*OR with statistical significance;

^astudies with more than 500 participants;

^bstudies with less than 500 participants;